TCT-589 Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in diabetic patients: 5 year follow up from the COMPARE I trial  by Vlachojannis, Georgios J. et al.
Table 1. Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
Baseline RVD (post-procedure) 3.000.37 3.080.35 0.21
6-month angiographic/IVUS
In-stent Late Lumen Loss 0.120.15 0.670.47 < 0.001
% neointimal volume 3.64.2 20.714.2 <0.001
Clinical Results
6-month DoCE (%) 2.7 3.2 1
Clinically-indicated TLR 1.8 3.2 0.52
12-month DoCE (%) 2.7 3.2 1
Clinically-indicated TLR 1.8 3.2 0.52
24-month DoCE (%) 2.7 3.2 1
Clinically-indicated TLR 1.8 3.2 0.52
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: The DESyne BD NECSS demonstrated non-inferiority and superi-
ority over Endeavor for in-stent late lumen loss at 6 months. Clinical events
remained low through 24 months; clinical results through 36 months will be
presented.
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Background: The SYNTAX trial represents the most comprehensive comparison of
percutaneous coronary intervention (PCI) and coronary artery bypass grafting
(CABG). Newer generation everolimus-eluting stents (Xience V; EES) have how-
ever been shown to have superior efﬁcacy and safety proﬁle compared to ﬁrst gen-
eration paclitaxel-eluting stents (Taxus Liberté; PES) used in the SYNTAX trial. As
to whether outcomes in the SYNTAX trial would have changed using the newer
generation EES is unsettled.
Methods: COMPARE is a prospective, randomized, single-center, all-comer trial
comparing EES to PES (1:1). As of present is the only randomized trial comparing
EES to PES in an all-comers population, which included complex multi-vessel (MV)
and/or left main (LM) disease, and had an independent adjudicated 5-year follow-up.
To mirror the SYNTAX population, a sub-analysis of COMPARE was performed in
subjects undergoing PCI for MV and/or LM disease (n¼466; 234 treated with PES
and 232 with EES). For both trials identical adjudicated composite endpoint major
adverse cardiac events (MACE: death, myocardial infarction, or target vessel revas-
cularization) were used at 5 years. Results were stratiﬁed by anatomical complexity
using the SYNTAX score.
Results: The incidence of MACE in COMPARE and SYNTAX with EES, PES or
CABG are tabulated.SYNTAX score COMPARE trial
MACE (%)
SYNTAX trial
MACE (%)
PES
(n¼234)
EES
(n¼232)
PES
(n¼871)
CABG
(n¼805)
<23 (low) 29.5 18.0 30.8 24.7
23-32 (intermediate) 40.9 18.6 34.3 22.1
‡33 (high) 45.5 36.4 42.2 22.4Conclusions: The results of this analysis suggest that in subjects with MV and/or
LM disease, newer generation EES might be superior to CABG in patients with low
SYNTAX score, and equivalent in intermediate SYNTAX score, latter group
currently recommended for CABG. Only the high SYNTAX score group showed a
clear long-term beneﬁt of CABG over PCI irrespective of stent type used. Newer
generation drug eluting stents may allow for further reﬁnement of the boundaries
between PCI and CABG, which may have important clinical and economical
implications.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteTCT-588
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Background: The multicenter, prospective, randomized, single-blinded, investigator-
initiated DUTCH PEERS (TWENTE II) “All Comers” Trial demonstrated at 1-year
follow-up the non-inferiority of third-generation Resolute Integrity zotarolimus-
eluting stents (Medtronic Vascular, Santa Rosa, CA) versus Promus Element ever-
olimus-eluting stents (Boston Scientiﬁc, Natick, MA), based on a similar incidence of
the primary endpoint target vessel failure (TVF), a composite of cardiac death, target
vessel revascularization (TVR), or myocardial infarction (MI). No other follow-up
data beyond 12 months have been published from a randomized head-to-head com-
parison of both stents.
Methods: In 4 study centers in the Netherlands, 1,811 patients were 1:1 randomly
assigned to treatment with one of both stents. Patients with any clinical syndrome, any
lesion type, and any number of lesions or vessels to be treated were included. Study
monitoring and clinical event adjudication were performed by two independent Dutch
contract research organizations (Diagram, Zwolle, and Cardialysis, Rotterdam,
respectively).
Results: DUTCH PEERS examines an all-comer patient population that included 59%
of patients with acute coronary syndromes (20% of all patients presented with an acute
STEMI) and 66% of patients with complex target lesions. We will compare for both
stent groups the 2-year incidence of TVF (primary endpoint) and various secondary
endpoints, including individual components of the primary endpoint, the incidence of
stent thrombosis, and other composite endpoints, such as target lesion failure, major
adverse cardiac events, and the patient-oriented composite endpoint. In addition, we
will report the outcome of patients with longitudinal stent deformation after discon-
tinuation of dual anti-platelet therapy.
Conclusions: Clinical outcome of the DUTCH PEERS trial at 2-year follow-up will
be presented.
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Background: Long-term comparison data of the current generation everolimus-
eluting stent (Xience V; EES) with the ﬁrst generation paclitaxel-eluting stent
(Taxus Liberté; PES) in an all-comers diabetic cohort undergoing percutaneous
coronary intervention (PCI) are scarce. Initial results at 2 year follow-up indi-
cated no differences in clinical outcomes between the two stent types in diabetic
patients.
Methods: The COMPARE I study was a prospective, randomized, single-center, all-
comer trial randomly allocating (1:1) patients to receive either EES or PES. It is to
date the only randomized trial comparing EES to PES in a true all-comers popu-
lation with an independent adjudicated 5-year follow-up. Randomization was strat-
iﬁed by the presence of diabetes. The primary endpoint was major adverse
cardiovascular events (MACE) deﬁned as the composite of the safety endpoints
death or myocardial infarction (MI) and the efﬁcacy endpoint target vessel revas-
cularization (TVR).
Results: Of the 1800 study patients, 325 patients were diabetic (18.1%) of whom 153
were treated with EES and 172 with PES. At 5 years EES reduced MACE compared
to PES in non-diabetic patients (17.1% vs. 23.0%, p< 0.01) with signiﬁcant reduction
in MI (6.6% vs. 11.1%, p< 0.01), TVR (7.0% vs. 10.4%, p¼0.02), and deﬁnite or
probable stent thrombosis (2.6% vs. 5.5%, p< 0.01). In the diabetic patients, EES
compared to PES reduced MACE (24.8% vs. 34.3%, p¼0.06) and TVR (9.2% vs.
15.7%, p¼0.08) without reaching statistical signiﬁcance. The 5 year outcomes are
tabulated.nts - Drug-eluting: Randomized Trials B171
Events at 1 Year
BES EES
P-value(n¼3412) (n¼2530)
All-cause death 2.0% (68) 2.0% (50) 1.0
Cardiac death 1.1% (39) 1.0% (26) 0.71
Myocardial infarction 3.1% (104) 2.9% (73) 0.76
Target lesion revascularization (All) 3.4% (115) 3.5% (88) 0.83
Target lesion revascularization (CD) 2.5% (84) 2.5% (63) 1.0
Target vessel revascularization (All) 5.0% (172) 5.0% (127) 1.0
Target vessel revascularization (CD) 3.6% (122) 3.8% (97) 0.63
Stent thrombosis (deﬁnite) 0.5% (17) 0.2% (5) 0.08
Stent thrombosis (deﬁnite / probable) 0.5% (18) 0.4% (10) 0.57
Target vessel failure 6.4% (219) 6.7% (169) 0.71
Diabetic Patients Non-Diabetic Patients
Events at 5 years
EES
(n¼153)
PES
(n¼172)
p-
value
EES
(n¼744)
PES
(n¼730)
p-
value
Death 15.7% (24) 14.5% (25) 0.77 7.7% (57) 9.3% (68) 0.25
Myocardial Infarction 9.2% (14) 13.4% (23) 0.23 6.6% (49) 11.1% (81) <0.01
Target Vessel
Revascularization
9.2% (14) 15.7% (27) 0.08 7.0% (52) 10.4% (76) 0.02
Target Lesion
Revascularization
7.2% (11) 11.0% (19) 0.23 6.0% (45) 9.2% (67) 0.02
Def./Prob. Stent
Thrombosis
5.9% (9) 7.6% (13) 0.55 2.6% (19) 5.5% (40) <0.01
MACE (Primary
Endpoint)
24.8% (38) 34.3% (59) 0.06 17.1% (127) 23.0% (168) <0.01
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: At 5-years EES was superior with regards to efﬁcacy and safety to
PES in non-diabetic patients. In diabetic patients a late trend towards reduction of
MACE was observed with EES compared to PES, mainly driven by a lower rate
of TVR.
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Background: We sought to investigate the long-term outcomes of an abluminal
groove-ﬁlled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort
Medical, Shanghai, China) compared to an everolimus-eluting stent (EES) XIENCE V
in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions < ¼24
mm in length and a coronary artery >¼2.25 to < ¼4.0 mm in diameter were enrolled
in the TARGET I study, a prospective, randomized, non-inferiority trial. The primary
endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary
endpoint, target lesion failure (TLF), was deﬁned as the composite of cardiac death,
target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion
revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6- and 12-month,
and annually up to 5 years for all enrolled patients. All adverse clinical events were
adjudicated by an independent committee.
Results: Previously reported results demonstrated FIREHAWK stent was non-inferior
to XIENCE V EES for the primary endpoint of 9-month in-stent LLL (0.130.24 mm
vs. 0.130.18 mm, p¼0.94; difference and 95% conﬁdence interval 0.00 [-0.04,
0.04] mm; p for non-inferiority < 0.0001), and had a comparable clinical outcome at
2 years. There were still no signiﬁcant differences between the two groups up to 3
years, and no deﬁnite/probable stent thrombosis occurred in FIREHAWK group.
(Table)Table. Clinical Outcomes through 3 Years
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Clinical Follow-Up, % (n/N) 99.6
(226/
227)
100
(231/
231)
0.50 99.6
(226/
227)
100
(231/
231)
0.50 97.4
(221/
227)
98.7
(228/
231)
0.34
Death, % (n) 0.4 (1) 0.9 (2) 1.00 0.4 (1) 0.9 (2) 1.00 1.8 (4) 1.8 (4) 1.00
Cardiac Death 0.4 (1) 0 (0) 1.00 0.4 (1) 0 (0) 1.00 0.9 (2) 0.4 (1) 0.62
Myocardial Infarction, % (n) 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50 1.4 (3) 3.1 (7) 0.34
Q Wave MI 0 (0) 0 (0) - 0 (0) 0 (0) - 0.0 (0) 0.4 (1) 1.00
Non Q Wave MI 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50 1.4 (3) 2.6 (6) 0.50
TV-MI 1.3 (3) 1.7 (4) 1.00 1.3 (3) 1.7 (4) 1.00 1.4 (3) 2.2 (5) 0.72
iTLR, % (n) 0.4 (1) 0.4 (1) 1.00 0.9 (2) 0.9 (2) 1.00 1.8 (4) 1.3 (3) 0.75
Any Revascularization, % (n) 1.8 (4) 4.8 (11) 0.07 2.2 (5) 6.1 (14) 0.04 4.5 (10) 7.5 (17) 0.19
TLF, % (n) 2.2 (5) 2.2 (5) 1.00 2.7 (6) 2.6 (6) 0.97 4.1 (9) 3.5 (8) 0.75
PoCE (composite of all cause death,
all MI, and any revascularization), % (n)
3.5 (8) 7.4 (17) 0.07 4.0 (9) 8.7 (20) 0.04 7.2 (16) 11.0 (25) 0.17
Deﬁnite/Probable Stent Thrombosis, %
(n)
0 (0) 0 (0) - 0 (0) 0 (0) - 0.0 (0) 0.4 (1) 1.00
B172 JACC Vol 64/11/Suppl B j SeptemberConclusions: In the multicenter randomized TARGET I trial, the 3-year follow-up
results conﬁrmed that the novel FIREHAWK stent had a durable safety and efﬁcacy
proﬁle, which was comparable to the XIENCE V EES for the treatment of single de
novo native coronary lesions. (ClinicalTrials.gov Identiﬁer: NCT01196819)
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Background: Drug-eluting stents with biodegradable polymers have been developed
to reduce the risk of very late adverse events. Distinct studies have indicated non-
inferiority of the biodegradable polymer-coated biolimus-eluting stent (Nobori;
BES) compared to the durable polymer-coated everolimus-eluting stent (Xience or
Promus; EES) with regards to safety and efﬁcacy at 1 year. However, these trials
were not powered to detect differences in low-frequency events.
Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned
5942 patients to BES or EES and is at present the largest pooled analysis of BES in
all-comers requiring percutaneous coronary intervention (PCI). The pre-speciﬁed
composite endpoint was target vessel failure (TVF) deﬁned as cardiac death, target
vessel related myocardial infarction (MI), or clinical-indicated target vessel revascu-
larization (TVR-CD).
Results: The pooled unadjusted 1-year clinical outcomes of the 5942 study patients
(8094 lesions) are tabulated. Covariate adjusted analyses accounting for baseline im-
balances between trials conﬁrmed non-signiﬁcant differences between stent type and
clinical outcomes. The trend for a higher deﬁnite stent thrombosis rate in the BES group
was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60]; p¼0.16).Conclusions: At 1-year the biodegradable polymer-coated BES has similar safety and
efﬁcacy outcomes as the durable polymer-coated EES. Longer follow-up data is
needed to determine the role of biodegradable polymer-coated BES in real world
clinical practice.
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Background: These are the ﬁrst long-term randomized adjudicated trial data of ﬁve
year results of the Genous bio-engineered endothelial progenitor cell capturing stent
(OrbusNeich BV, Fort Lauderdale, FL, USA) compared with a paclitaxel-eluting
stent(PES).
Methods: In this prospective randomized trial, patients with de-novo coronary artery
lesions carrying a high risk of restenosis (chronic total occlusion,lesion length >
23mm,vessel diameter < 2.8mm or any lesion in a diabetic patient) were randomized
1:1 to the Genous or a PES. The current primary endpoint is adjudicated target vessel
failure (TVF) at 5-years, a composite of cardiac death, myocardial infarction (MI) and
target vessel revascularization. Clinical event rates were estimated by Kaplan-Meier
method and compared with a log-rank test.
Results: A total of 193 patients were included with complete follow-up in 97% of the
subjects. The primary endpoint of TVF was similar at 5 years with Genous 23.8% vs13–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Randomized Trials
